
ATIVESITE | Perspectives on Metastatic Hormone-Sensitive Prostate Cancer | Bayer
Professor Daniel George, MD, Director of GU Oncology at Duke University in North Carolina, shares his thoughts on types of prostate cancer, the unmet medical needs in metastatic-hormone sensitive prostate cancer, advances in prostate cancer treatment, as well as the importance of quality of life for people living with the disease.
00:00 – Introduction
00:07 – What are the different disease stages in prostate cancer?
01:04 – What is metastatic hormone-sensitive prostate cancer?
01:22 – What is the prognosis for those diagnosed with metastatic hormone-sensitive prostate cancer?
01:53 – What does the treatment landscape look like in metastatic hormone-sensitive prostate cancer?
02:39 – What are the current unmet medical needs in metastatic hormone-sensitive prostate cancer?
03:27 – Which treatment outcomes are most important to patients with metastatic hormone-sensitive prostate cancer?
03:50 – How important is maintaining quality of life for you when you discuss treatment options with your patients?
04:57 – What impact can treatment related adverse events have on treatment adherence and can this impact patient outcomes?
05:43 – What can the medical community do to continue supporting patients living with metastatic hormone-sensitive prostate cancer?
Source Bayer YouTube